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                                                                                                     The role of CMV infection in COPD 
Chronic obstructive pulmonary disease (COPD) is characterized by chronic irreversible 
inflammation and progressive decline in lung function. While smoking and other environmental 
agents (e.g. air pollutants) are common causes of COPD, the major challenges in managing this 
condition are the persistent inflammation and functional deterioration which are not reversed by 
removal of precipitating agents (e.g. smoking cessation) or treatment with anti-inflammatory agents. 
We hypothesized that the reactivation of latent CMV infection may trigger expansion of  
proinflammatory CD28null T-cells and hence promote sysmetic inflammation in patients with 
COPD. This study presents novel data showing increased levels of CMV-reactive IgM and IgG in 
COPD patients compared to controls. This paralleled observed increases in markers of sytemic 
inflammation ex vivo and proportions of circulating CD28null T-cells. This mechanism may explain 
the persistent inflammation in COPD patients. 
 
COPD is a leading cause of global mortality and morbidity which affects mostly smokers and the 
elderly. It involves airway and systemic inflammation and progressive decline in lung function due 
to airway damage and airflow obstruction. Acute exacerbations of COPD (AECOPD), defined as 
significant worsening of COPD symptoms requiring treatment modifications and/or hospitalization, 




Acute respiratory viral infections (e.g. influenza) are commonly associated with AECOPD, and 
latent adenoviral infections have also been implicated
2
. However no studies have addressed the 
roles of herpes viruses such as cytomegalovirus (CMV) that persist in a latent state and can be 
reactivated by inflammation or immunosuppression. CMV infections are usually asymptomatic in 
healthy individuals but can cause life-threatening end-organ disease in immune-compromised 
individuals (e.g. transplant recipients or HIV patients). Whilst symptomatic CMV diseases are rare 
in COPD patients, chronic inflammation or treatment with corticosteroids may promote CMV-
related complications including pneumonitis and esophagitis
3
.  
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As COPD is a disease of old age, it is valid to consider how it may be affected by the impact of 
repeated CMV reactivations on the immune system. Furthermore, both COPD and CMV replication 
increase the incidence of age-associated systemic co-morbidities (e.g. cardiovascular diseases) and 
are associated with expanded populations of circulating CD28null T-cells (marker of immune 
senescence/aging) that are pro-inflammatory
1, 4-7
. Therefore, we investigated the link between 
COPD and levels of CMV-reactive antibodies in the context of chronic inflammation and T-cell 
senescence.  
 
The study was approved by the Ethics Committee at the Royal Perth Hospital and all participants 
gave informed consent. We recruited AECOPD patients (n=21) who were admitted for exacerbation 
to the Royal Perth Hospital Emergency Department (Western Australia) and stable COPD (sCOPD) 
patients (n=33) who were previous smokers (>15 pack-years and ceased smoking >5 years earlier) 
from a dedicated COPD clinic at Royal Perth Hospital. The diagnosis and severity of COPD were 
established using the Global Initiative for Chronic Obstructive Lung Disease guidelines (Stages 2-
4). All patients had been treated with anticholinergic drugs, long-acting beta agonists and inhaled 
corticosteroids but none were receiving systemic corticosteroids or had diabetes, neuromuscular, 
allergic or rheumatological disease. Healthy age-matched non-smoking controls with no clinical 
evidence of COPD were included (n=33).  
 
Levels of IgG and IgM reactive with a lysate of CMV-infected fibroblasts (CMV-lysate), CMV 
glycoprotein-B (CMV-gB) and CMV immediate early-1 antigen (CMV-IE-1) in plasma were 
measured by in-house ELISAs
8
. Three antigen preparations of CMV were used in our assay because 
CMV-lysate contains several CMV antigens, whilst antibodies to CMV-IE-1 arise during early 
CMV infection and antibodies against CMV-gB denotes previous infection. Plasma levels of 
soluble tumour necrosis factor receptor-1 (sTNFR1), a marker of systemic inflammation, were 
measured using a commercial ELISA kit (R&D Systems, Minneapolis, MN, USA)
8
. Proportions of 





 T-cells were quantified by flow cytometry after staining peripheral blood 
mononuclear cells with anti-CD3-APC-H7, CD4-V500, CD8-PerCP-Cy5.5 and CD28-PE-Cy7 (BD 
Biosciences, San Jose, CA, USA). 
 
Levels of IgM and IgG reactive with CMV-lysate were higher in AECOPD (p=0.022 & 0.02 
respectively) and sCOPD patients (0.002 & 0.014, respectively) than controls, but did not differ 
between AECOPD and sCOPD patients (Figure 1A & 1B). Similar trends were observed with titers 
of IgG reactive with CMV-gB (Figure 1C), whilst IgG reactive with CMV-IE-1 were similar 
between groups (Figure 1D). There were higher proportions of CMV sero-negative individuals 
amongst controls than patients (24% = 5/21 AECOPD; 21% = 7/33 sCOPD; 36% = 12/33 controls). 
These individuals had <300 U/mL IgG (below the broken line; Figure 1B), using a cut-off defined 
by 11 individuals deemed CMV sero-negative using a commercial microparticle enzyme 
immunoassay (Abbott Laboratories, IL, USA). After the exclusion of CMV sero-negative subjects, 
levels of IgG reactive with CMV-lysate were still higher in AECOPD and sCOPD patients (p=0.003 
& 0.02, respectively) than controls. 
 
AECOPD and sCOPD patients exhibited higher levels of sTNFR1 than controls (p<0.001 and 
0.007, respectively). Levels of sTNFR1 were also higher in AECOPD than sCOPD patients 
(p=0.016; Figure 1E). Levels of IgM and IgG reactive with CMV antigens correlated with sTNFR1 
levels (r=0.25-0.28, p=0.006-0.02), but not with the level of total IgG or lung function (data not 
shown). The plasma concentration of total IgG was lower in AECOPD than controls (p=0.018), but 
similar to controls in sCOPD patients (p=0.81; Figure 1F). Therefore, elevation of CMV-reactive 
antibodies was specific and did not reflect B-cell activation because total IgG levels were not 
elevated in COPD patients.  
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CMV reactivation has been associated with chronic inflammation
4
. In a murine model, 
inflammatory cytokines (e.g. TNF) or allogeneic transplantation induced CMV reactivations
9
. 
Inflammation in COPD patients (triggered by precipitates including tobacco and air pollution) may 
promote CMV reactivation thus perpetuating low grade inflammation. In this study, the smoking 
history of COPD patients (pack-years) correlated positively with CMV-reactive antibody (r=0.35-
0.46, p=0.004-0.03). The correlation between smoking history and the level of CMV-reactive 
antibodies suggests an interaction of these two inflammatory stimuli in the pathogenesis of COPD.  
 




 T-cells were higher in sCOPD patients than controls 





cells correlated with levels of IgG reactive with CMV-lysate (r=0.48, p<0.001 & r=0.42, p=0.001, 
respectively), CMV-gB (r=0.42, p=0.001 & r=0.34, p=0.01, respectively) and CMV-IE-1 (r=0.43, 
p<0.001 & r=0.31, p=0.02, respectively). 
 
The loss of CD28 expression on T-cells reflects immune aging arising from chronic antigen 
stimulation. These senescent T-cells have reduced telomere length, aberrant DNA methylation and 






 T-cells have been 
implicated in COPD and autoimmune diseases
5, 6, 10
. In COPD, CD28null T-cells produce more 




. Smokers without COPD 




. In patients with multiple sclerosis and rheumatoid 
arthritis, CD28null T-cells were mostly reactive with CMV antigens rather than self-antigens and 
were resistant to suppressive action of regulatory T-cells
10
. This suggests that the accumulation of 
CD28null T-cells in COPD is more likely due to CMV reactivation than smoking, thus promoting 
chronic inflammation and further enhancing both diseases. 
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In conclusion, our study supports a role for CMV in the pathogenesis of COPD. Reactivation of 
CMV may trigger the induction of CD28null T-cells and promote systemic inflammation 
characteristic of COPD patients. Future studies investigating the role of T-cells in COPD should 
consider the CMV sero-status of patients since CMV plays a role in mediating chronic 
inflammation and augmenting the function of inflammatory T-cells.  
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Figure legend 
 
Figure 1 – Plasma levels of CMV-reactive IgM and IgG, sTNFR1 and total IgG and 
circulating proportions of CD28null T-cells in patients with AECOPD and sCOPD compared 
with healthy controls. The levels of IgM against CMV-lysate (A), IgG against CMV-lysate (B), 
IgG against CMV-gB (C), IgG against CMV-IE-1 (D), sTNFR1 (E) and total IgG (F) in plasma 
were measured by ELISA. Circulating proportions of CD28null CD4
+
 (G) and CD8
+
 T-cells (H) 
were quantified by flow cytometry. Non-parametric Mann-Whitney test was used to compare the 
medians between AECOPD, sCOPD and healthy controls using the Prism 5.04 (GraphPad 
Software, La Jolla, CA). Horizontal lines denote median and only significant p-values (p<0.05) 
were presented on graphs.  
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